Abstract：
OBJECTIVE: To investigate the effectiveness of platelet-rich plasma (PRP) injection into the olfactory clefts of coronavirus disease 2019 (COVID-19) patients with persistent olfactory dysfunction (OD).
METHODS: Controlled study.
METHODS: Multicenter study.
METHODS: From March 2022 to November 2022, COVID-19 patients with persistent OD were recruited from three European hospitals to undergo PRP injections into the olfactory clefts. Olfactory function was evaluated at baseline and 10 weeks postinjection with the Olfactory Disorder Questionnaire (ODQ) and threshold, discrimination, and identification (TDI) test. Data were compared with a control group of untreated patients.
RESULTS: Eighty-one patients who underwent PRP injection and 78 controls were included. Sixty-five PRP patients (80.3%) experienced subjective smell improvement after a mean duration of 3.4 ± 1.9 weeks. The parosmia, life quality statement, and ODQ sub- and total scores significantly decreased from pre- to 10-week postinjection in the PRP group. The TDI sub- and total scores significantly increased 10 weeks postinjection. In controls, the ODQ score did not change over time, while the discrimination, identification, and total TDI scores significantly increase after 10 weeks of follow-up. The 10-week TDI and ODQ scores were significantly better in the PRP group compared with the controls.
CONCLUSIONS: Patients who underwent PRP injection reported better 10-week subjective and objective smell outcomes than controls. Future randomized-controlled studies using saline injection into the olfactory cleft of controls are needed to determine the superiority of PRP over placebo.
METHODS: Controlled study.
METHODS: Multicenter study.
METHODS: From March 2022 to November 2022, COVID-19 patients with persistent OD were recruited from three European hospitals to undergo PRP injections into the olfactory clefts. Olfactory function was evaluated at baseline and 10 weeks postinjection with the Olfactory Disorder Questionnaire (ODQ) and threshold, discrimination, and identification (TDI) test. Data were compared with a control group of untreated patients.
RESULTS: Eighty-one patients who underwent PRP injection and 78 controls were included. Sixty-five PRP patients (80.3%) experienced subjective smell improvement after a mean duration of 3.4 ± 1.9 weeks. The parosmia, life quality statement, and ODQ sub- and total scores significantly decreased from pre- to 10-week postinjection in the PRP group. The TDI sub- and total scores significantly increased 10 weeks postinjection. In controls, the ODQ score did not change over time, while the discrimination, identification, and total TDI scores significantly increase after 10 weeks of follow-up. The 10-week TDI and ODQ scores were significantly better in the PRP group compared with the controls.
CONCLUSIONS: Patients who underwent PRP injection reported better 10-week subjective and objective smell outcomes than controls. Future randomized-controlled studies using saline injection into the olfactory cleft of controls are needed to determine the superiority of PRP over placebo.
摘要：
目的：探讨富血小板血浆（PRP）在持续嗅觉功能障碍（OD）的冠状病毒病（COVID-19）患者嗅裂中的应用效果。
方法：对照研究。
方法：多中心研究。
方法：从2022年3月至2022年11月，从三家欧洲医院招募了患有持续性OD的COVID-19患者，将PRP注射到嗅裂中。在基线和注射后10周用嗅觉障碍问卷（ODQ）和阈值评估嗅觉功能，歧视,和识别（TDI）测试。将数据与未治疗患者的对照组进行比较。
结果：纳入了81例接受PRP注射的患者和78例对照。65名PRP患者（80.3％）在平均持续时间为3.4±1.9周后主观嗅觉得到改善。在这个问题上,生活质量声明，在PRP组中，从注射前到注射后10周，ODQ分和总分显着降低。TDI分和总分在注射后10周显着增加。在控件中，ODQ分数没有随时间变化，而歧视,identification,随访10周后，TDI总分显著增加。与对照组相比，PRP组的10周TDI和ODQ评分明显更好。
结论：接受PRP注射的患者10周主观和客观嗅觉结果优于对照组。未来需要使用生理盐水注射到对照组嗅裂中的随机对照研究，以确定PRP优于安慰剂。
方法：对照研究。
方法：多中心研究。
方法：从2022年3月至2022年11月，从三家欧洲医院招募了患有持续性OD的COVID-19患者，将PRP注射到嗅裂中。在基线和注射后10周用嗅觉障碍问卷（ODQ）和阈值评估嗅觉功能，歧视,和识别（TDI）测试。将数据与未治疗患者的对照组进行比较。
结果：纳入了81例接受PRP注射的患者和78例对照。65名PRP患者（80.3％）在平均持续时间为3.4±1.9周后主观嗅觉得到改善。在这个问题上,生活质量声明，在PRP组中，从注射前到注射后10周，ODQ分和总分显着降低。TDI分和总分在注射后10周显着增加。在控件中，ODQ分数没有随时间变化，而歧视,identification,随访10周后，TDI总分显著增加。与对照组相比，PRP组的10周TDI和ODQ评分明显更好。
结论：接受PRP注射的患者10周主观和客观嗅觉结果优于对照组。未来需要使用生理盐水注射到对照组嗅裂中的随机对照研究，以确定PRP优于安慰剂。
